6l9l - Revision history

OCA at 10:53, 22 November 2023

2023-11-22T10:53:44Z

←Older revision		Revision as of 10:53, 22 November 2023
Line 1:		Line 1:

-	====	+	==1D4 TCR recognition of H2-Ld a1a2 A5 Peptide Complexes==
-	<StructureSection load='6l9l' size='340' side='right'caption='[[6l9l]]' scene=''>	+	<StructureSection load='6l9l' size='340' side='right'caption='[[6l9l]], [[Resolution\|resolution]] 2.40Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id= OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol= FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[6l9l]] is a 8 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6L9L OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6L9L FirstGlance]. <br>
-	</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6l9l FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6l9l OCA], [https://pdbe.org/6l9l PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6l9l RCSB], [https://www.ebi.ac.uk/pdbsum/6l9l PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6l9l ProSAT]</span></td></tr>	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 2.399Å</td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6l9l FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6l9l OCA], [https://pdbe.org/6l9l PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6l9l RCSB], [https://www.ebi.ac.uk/pdbsum/6l9l PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6l9l ProSAT]</span></td></tr>
	</table>		</table>
		+	== Function ==
		+	[https://www.uniprot.org/uniprot/HA1L_MOUSE HA1L_MOUSE] Involved in the presentation of foreign antigens to the immune system.
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	Tumors frequently express unmutated self-tumor-associated antigens (self-TAAs). However, trial results using self-TAAs as vaccine targets against cancer are mixed, often attributed to deletion of T cells with high-affinity receptors (TCRs) for self-TAAs during T cell development. Mutating these weak self-TAAs to produce higher affinity, effective vaccines is challenging, since the mutations may not benefit all members of the broad self-TAA-specific T cell repertoire. We previously identified a common weak murine self-TAA that we converted to a highly effective antitumor vaccine by a single amino acid substitution. In this case the modified and natural self-TAAs still raised very similar sets of CD8 T cells. Our structural studies herein show that the modification of the self-TAA resulted in a subtle change in the major histocompatibility complex I-TAA structure. This amino acid substitution allowed a dramatic conformational change in the peptide during subsequent TCR engagement, creating a large increase in TCR affinity and accounting for the efficacy of the modified self-TAA as a vaccine. These results show that carefully selected, well-characterized modifications to a poorly immunogenic self-TAA can rescue the immune response of the large repertoire of weakly responding natural self-TAA-specific CD8 T cells, driving them to proliferate and differentiate into functional effectors. Subsequently, the unmodified self-TAA on the tumor cells, while unable to drive this response, is nevertheless a sufficient target for the CD8 cytotoxic effectors. Our results suggest a pathway for more efficiently identifying variants of common self-TAAs, which could be useful in vaccine development, complementing other current nonantigen-specific immunotherapies.
		+
		+	Structures suggest an approach for converting weak self-peptide tumor antigens into superagonists for CD8 T cells in cancer.,Wei P, Jordan KR, Buhrman JD, Lei J, Deng H, Marrack P, Dai S, Kappler JW, Slansky JE, Yin L Proc Natl Acad Sci U S A. 2021 Jun 8;118(23):e2100588118. doi: , 10.1073/pnas.2100588118. PMID:34074778<ref>PMID:34074778</ref>
		+
		+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
		+	</div>
		+	<div class="pdbe-citations 6l9l" style="background-color:#fffaf0;"></div>
		+
		+	==See Also==
		+	*[[T-cell receptor 3D structures\|T-cell receptor 3D structures]]
		+	== References ==
		+	<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Homo sapiens]]
	[[Category: Large Structures]]		[[Category: Large Structures]]
-	[[Category: ~~Z-disk~~]]	+	[[Category: Wei PC]]
		+	[[Category: Yin L]]

OCA at 06:47, 24 March 2021

2021-03-24T06:47:40Z

←Older revision		Revision as of 06:47, 24 March 2021
Line 3:		Line 3:
	<StructureSection load='6l9l' size='340' side='right'caption='[[6l9l]]' scene=''>		<StructureSection load='6l9l' size='340' side='right'caption='[[6l9l]]' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id= OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://proteopedia.org/fgij/fg.htm?mol= FirstGlance]. <br>	+	<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id= OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol= FirstGlance]. <br>
-	</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://proteopedia.org/fgij/fg.htm?mol=6l9l FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6l9l OCA], [~~http~~://pdbe.org/6l9l PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=6l9l RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/6l9l PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=6l9l ProSAT]</span></td></tr>	+	</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6l9l FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6l9l OCA], [https://pdbe.org/6l9l PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6l9l RCSB], [https://www.ebi.ac.uk/pdbsum/6l9l PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6l9l ProSAT]</span></td></tr>
	</table>		</table>
	__TOC__		__TOC__

OCA at 09:31, 18 November 2020

2020-11-18T09:31:31Z

←Older revision		Revision as of 09:31, 18 November 2020
Line 1:		Line 1:
-	'''Unreleased structure'''

-	~~The entry~~ 6l9l ~~is ON HOLD until Paper Publication~~	+	====
-		+	<StructureSection load='6l9l' size='340' side='right'caption='[[6l9l]]' scene=''>
-	~~Authors~~:	+	== Structural highlights ==
-		+	<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id= OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol= FirstGlance]. <br>
-	~~Description~~:	+	</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=6l9l FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6l9l OCA], [http://pdbe.org/6l9l PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6l9l RCSB], [http://www.ebi.ac.uk/pdbsum/6l9l PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6l9l ProSAT]</span></td></tr>
-	[[Category: ~~Unreleased~~ Structures]]	+	</table>
		+	__TOC__
		+	</StructureSection>
		+	[[Category: Large Structures]]
		+	[[Category: Z-disk]]

OCA at 07:19, 1 April 2020

2020-04-01T07:19:38Z

←Older revision		Revision as of 07:19, 1 April 2020
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 6l9l is ON HOLD	+	The entry 6l9l is ON HOLD until Paper Publication

	Authors:		Authors:

OCA: Protected "6l9l" [edit=sysop:move=sysop]

2019-11-20T13:26:01Z

Protected "6l9l" [edit=sysop:move=sysop]

←Older revision

Revision as of 13:26, 20 November 2019

OCA: New page: '''Unreleased structure''' The entry 6l9l is ON HOLD Authors: Description: Category: Unreleased Structures

2019-11-20T13:25:59Z

New page: '''Unreleased structure''' The entry 6l9l is ON HOLD Authors: Description: Category: Unreleased Structures

New page

'''Unreleased structure'''

The entry 6l9l is ON HOLD

Authors:

Description:
[[Category: Unreleased Structures]]